Research use only — not for human or veterinary use
DSIP For Sale — Delta Sleep-Inducing Peptide Vials and Nasal Spray
DSIP, the delta sleep-inducing peptide, is a nine-residue neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was isolated in the 1970s from the cerebral venous blood of rabbits in induced slow-wave sleep, and named for the delta-wave EEG activity associated with that state. Despite fifty years of investigation its receptor has never been definitively identified, which makes it one of the more genuinely open questions in neuropeptide research. We supply DSIP as a lyophilized research vial and as a 10 mg nasal spray research format. For in vitro laboratory research only — not for human or veterinary use.
Compare DSIP Research Formats
The vial supports arbitrary working concentrations; the nasal spray is a fixed-format research article used where the delivery format itself is under study.
| Option | Format | Suited to | Product page |
|---|---|---|---|
| DSIP research vial | Lyophilized powder, single research vial | Concentration series, receptor-search and stability work | View DSIP research vial → |
| DSIP nasal spray 10 mg | Pre-formulated intranasal research format | Delivery-format, dissolution and formulation-stability research | View DSIP nasal spray 10 mg → |
What Is DSIP?
DSIP was identified by Monnier and Schoenenberger in Basel, who perfused blood from rabbits in electrically induced slow-wave sleep into recipient animals and isolated the fraction that transferred the EEG signature. The nine-residue sequence they eventually characterised has been synthesised routinely since, and it remains chemically straightforward to produce at high purity.
What has not been resolved is how it works. Unlike almost every other neuropeptide of comparable vintage, DSIP has no established receptor. Binding studies over several decades have produced inconsistent results, and the current position in the literature is that its effects may be mediated indirectly, possibly through modulation of other neurotransmitter systems, rather than through a dedicated receptor of its own.
That unresolved status is the honest framing for anyone buying it. DSIP is a research subject rather than a research tool: it is not a reliable positive control for anything, because there is no consensus mechanism against which to calibrate. Study designs should reflect that.
What the Mechanistic Literature Actually Shows
Reported findings span several unrelated systems. Some work describes modulation of corticotropin and somatotropin release; other studies report interactions with opioid and GABAergic signalling; still others examine effects on oxidative-stress markers. The breadth is striking, and it is one of the reasons the field has been slow to converge.
Endogenous presence is itself contested. DSIP-like immunoreactivity has been reported in a range of tissues, but immunoreactivity is not the same as identity, and antibody cross-reactivity with structurally related sequences is a plausible explanation for at least some reports.
For a laboratory this means orthogonal readouts matter more than usual. A single immunoassay result should not carry an interpretation on its own; pairing it with a mass-spectrometry-based measurement or a functional readout is the difference between a publishable observation and an artifact.
Research Applications
Common in vitro applications include receptor-search and binding-screen work across candidate GPCR panels, neurotransmitter-release assays in synaptosome or neuronal culture preparations, oxidative-stress marker panels, and stability studies examining the peptide's behaviour in biological matrices.
Comparative work with other sleep- and stress-associated peptides — selank, orexin-A, orexin-B — is common, both because those compounds have better-defined mechanisms and because contrast against a defined-mechanism peptide is often the clearest way to characterise an undefined one.
The nasal format supports a distinct line of enquiry: intranasal delivery research, where the questions concern formulation stability, spray characterisation, and mucosal-model permeability rather than the peptide's central biology.
- Candidate receptor binding and displacement screens
- Neurotransmitter release assays in neuronal preparations
- Comparative panels against selank and the orexins
- Intranasal formulation and permeability research
Vial vs. Nasal Spray Research Format
The lyophilized vial is the format for any study needing a defined working concentration. It supports mass-based reconstitution, serial dilution, and the flexibility that receptor-search work in particular requires, since candidate screens typically test across several orders of magnitude.
The 10 mg nasal spray is a pre-formulated research article. Its value is in studies where the formulation is the variable: spray-pattern and droplet characterisation, excipient compatibility, stability of the peptide in a liquid formulation over time, and permeability testing in mucosal tissue models.
The two are not substitutes. A nasal spray cannot be reliably diluted into a concentration series because its excipient system was not designed for that, and a reconstituted vial does not reproduce the formulation behaviour the spray exists to study.
Storage and Handling
Lyophilized DSIP vials should be stored frozen, sealed, and protected from light and moisture. The peptide contains a tryptophan residue, which is the most photo-labile of the proteinogenic amino acids, so light protection is a genuine stability requirement here rather than a generic precaution.
Reconstitute with bacteriostatic water added down the vial wall and swirl gently until clear. The nine-residue sequence dissolves readily. Once in solution, keep the material refrigerated, in the dark, and use within a short window; oxidation of the tryptophan is the degradation route to watch and it is accelerated by light and by exposure to air.
The nasal spray format should be refrigerated, kept upright, and protected from light. Do not decant it into secondary containers for storage; the formulation's stability data applies to the supplied container and headspace.
Material Specifications
- Compound
- Delta sleep-inducing peptide (DSIP)
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Molecular formula
- C35H48N10O15
- Molar mass
- ≈ 848.8 g/mol
- Receptor
- Not definitively identified — active research question
- Purity
- ≥ 99% by reverse-phase HPLC
- Storage
- Sealed vials frozen; reconstituted and spray formats 2–8 °C
- Use
- In vitro laboratory research only
Purity, Testing & Certificates of Analysis
DSIP is released against reverse-phase HPLC purity criteria with mass-spectrometry identity confirmation. The tryptophan residue at position one gives the sequence a strong 280 nm absorbance, and monitoring that wavelength alongside 214 nm provides a sensitive early indicator of oxidative degradation that a single-wavelength method would miss.
The nasal spray format is additionally assessed for appearance and clarity at release, since a formulated liquid can show early degradation visually before it becomes measurable chromatographically.
Each shipment references a dated, lot-specific Certificate of Analysis recording purity, identity, water content, appearance and assay date, retrievable after purchase and published in the full COA library.
Research FAQ
What is DSIP?
DSIP is the delta sleep-inducing peptide, a nine-residue neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated in the 1970s from the venous blood of rabbits in induced slow-wave sleep. It is supplied as a research chemical for in vitro laboratory work only.
What receptor does DSIP act on?
No receptor has been definitively identified, despite five decades of investigation. Binding studies have produced inconsistent results and the current view is that its reported effects may be mediated indirectly through other neurotransmitter systems. This makes DSIP a research subject rather than a calibrated research tool.
What is DSIP used for in research?
Applications include candidate receptor binding and displacement screens, neurotransmitter release assays in neuronal preparations, oxidative-stress marker panels, comparative work against selank and the orexins, and intranasal formulation research using the spray format. No human or veterinary use is supported.
Should I buy the DSIP vial or the nasal spray?
Buy the lyophilized vial for any study needing a defined working concentration or a dilution series, which includes most receptor-search work. Buy the 10 mg nasal spray when the formulation itself is the variable — spray characterisation, excipient compatibility, or mucosal permeability modelling. They are not substitutes.
Why does DSIP need light protection specifically?
The sequence begins with tryptophan, the most photo-labile proteinogenic amino acid. Oxidation of that residue is the main degradation route, and it is accelerated by light and air exposure, so both the lyophilized vial and the reconstituted solution should be kept dark and the working window kept short.
What purity is your DSIP?
DSIP is released at ≥99% chromatographic purity by reverse-phase HPLC with mass-spectrometry identity confirmation. Release chromatography monitors 280 nm alongside 214 nm because the tryptophan absorbance provides a sensitive early indicator of oxidative degradation.
How should DSIP be stored?
Store sealed lyophilized vials frozen, protected from light and moisture. After reconstitution keep the solution refrigerated at 2–8 °C in the dark and use it within a short window. The nasal spray format should be refrigerated, kept upright in its supplied container, and protected from light.
Is DSIP a sleep aid?
No. DSIP is supplied strictly as a research chemical for qualified in vitro laboratory use. It is not a medicine, supplement, or sleep product, its mechanism is unresolved in the published literature, and we make no claims about effects in humans and provide no dosing guidance.
Research Resources
All products listed are supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary use. We do not provide dosing guidance or therapeutic recommendations, and nothing on this page describes a diagnosis, treatment, cure, or prevention of any condition.